Home » AMGEN TO BEGIN ARANESP STUDY
AMGEN TO BEGIN ARANESP STUDY
Amgen will initiate a Phase III, randomized, placebo-controlled, double-blind, multicenter, multinational trial to evaluate the effect of anemia treatment with darbepoetin alfa (aranesp) on morbidity and mortality in patients with heart failure.
Aranesp is a recombinant erythropoietic protein (a protein that stimulates production of oxygen-carrying red blood cells). It contains two additional sialic acid-containing carbohydrate chains than the Epoetin alfa molecule, resulting in more activity, with the added benefit of less-frequent administration.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
07May
-
14May
-
30May